Jonathan Yen-Wen Yu Sells 300 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 300 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $82.53, for a total value of $24,759.00. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $4,483,359.72. The trade was a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, August 25th, Jonathan Yen-Wen Yu sold 8,796 shares of Disc Medicine stock. The shares were sold at an average price of $83.12, for a total value of $731,123.52.
• On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The shares were sold at an average price of $82.64, for a total value of $66,442.56.
• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The stock was sold at an average price of $82.50, for a total transaction of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $72.50, for a total transaction of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON traded up $0.26 during midday trading on Wednesday, reaching $82.67. The company’s stock had a trading volume of 586,890 shares, compared to its average volume of 329,310. The firm has a market capitalization of $316.63 million, a PE ratio of -12.56 and a beta of 1.00. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50. The stock has a fifty day moving average of $76.56 and a 200 day moving average of $69.95. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.17. On average, equities analysts expect that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its position in shares of Disc Medicine by 8,273.0% during the 2nd quarter. California State Teachers Retirement System now owns 2,878,790 shares of the company’s stock valued at $210,555,000 after buying an additional 2,844,408 shares in the last quarter. AXQ Capital LP acquired a new position in Disc Medicine during the second quarter worth $441,000. Nykredit A S purchased a new position in Disc Medicine during the second quarter valued at $103,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Disc Medicine by 2.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 114,109 shares of the company’s stock worth $8,346,000 after buying an additional 3,219 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Disc Medicine by 0.3% during the second quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock worth $127,362,000 after purchasing an additional 5,975 shares during the period. 83.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Morgan Stanley reiterated an “overweight” rating and set a $90.00 price target on shares of Disc Medicine in a research report on Monday, August 17th. HC Wainwright boosted their price target on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded Disc Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Disc Medicine presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.50.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.